Product methodology
FAERS + Real-World Drug Interaction Surveillance
Source contract, normalization path, entity-graph join, refresh posture, and publication limits for this Branmoor product.
Status
In service. This product has a functional preview or paid engagement surface in the current site. The full licensed product may still include private exports, alerts, APIs, or buyer-specific diligence that are not exposed publicly.
Distribution Scope
Nationwide; TN prescribing context; Nashville medication-signal pages
Product Question
Surfaces adverse-event and interaction signals with utilization context.
Primary Sources
- FDA FAERS Public Dashboard and quarterly extracts — Adverse event reports
- State PDMP aggregate data (where public) — Prescribing pattern surveillance
- Medicare Part D Public Use Files — Polypharmacy and co-prescription patterns
- PubMed case report indexing — Published case literature
- FDA drug labeling (Structured Product Labeling) — Current labeling baseline for new-signal detection
Entity-Graph Join
`ndc`/RxCUI, drug name, manufacturer `irs_ein`, prescriber `npi`, county.
Publication Rule
Branmoor does not treat raw public records as the product. A surface is publishable only when the source record is dated, normalized, source-linked, and joined to the relevant Branmoor entity identifiers with enough confidence to state the limits of the result.
Current Methodology Note
v1 surfaces the top drugs by FAERS report volume with serious-event and fatality counts plus the top 10 reactions per drug — the primary-source counts. The paid Signal Surveillance layer adds disproportionality analysis (Information Component, EBGM, PRR), drug-drug interaction signal detection, cross-reference against the FDA SPL labeling for new-signal flagging, and polypharmacy patterns in Medicare Part D claims.
Limits
Coverage follows the underlying source. Missing state portals, gated APIs, PDF-only filings, suppressed fields, lagged agency refreshes, and entity-name ambiguity can all limit product completeness. Pending products are not marketed as live until those limits are documented on the product surface.
‹ FAERS + Real-World Drug Interaction Surveillance · All products